6533b7d0fe1ef96bd1259bc8

RESEARCH PRODUCT

Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism-Results from the thrombEVAL Study.

Christoph BickelPhilipp S. WildMichael LauterbachThomas MünzelKarl J. LacknerLisa EggebrechtHugo Ten CateHugo Ten CateVincent Ten CateMeike ColdeweyMarina Panova-noevaSebastian GöbelChristine Espinola-kleinMaike FoebelMarkus NaglerKarsten KellerJürgen H. Prochaska

subject

medicine.medical_specialtyANTITHROMBOTIC THERAPYPULMONARY-EMBOLISMvenous thromboembolismlcsh:Medicine030204 cardiovascular system & hematologyRate ratioWARFARINArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineORAL ANTICOAGULATION030212 general & internal medicineAdverse effectcoagulation serviceINR CONTROLNORMALIZED RATIO CONTROLPRACTICAL MANAGEMENTbusiness.industrySTROKE PREVENTIONlcsh:RHazard ratioWarfarinAtrial fibrillationGeneral Medicinemedicine.diseaseConfidence intervalMEDICAL-CAREPulmonary embolismvitamin K antagonistsATRIAL-FIBRILLATIONe-healthbusinessoral anticoagulation therapymedicine.drug

description

Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011&ndash

10.3390/jcm9103281https://pubmed.ncbi.nlm.nih.gov/33066188